Design of Dual COX-2 and 5-LOX Inhibitors with Iron-Chelating Properties Using Structure-Based and Ligand-Based Methods

被引:0
作者
Boskovic, Jelena [1 ]
Ruzic, Dusan [1 ]
Cudina, Olivera [1 ]
Nikolic, Katarina [1 ]
Dobricic, Vladimir [1 ]
机构
[1] Univ Belgrade, Fac Pharm, Dept Pharmaceut Chem, Belgrade, Serbia
关键词
Drug design; 3D-QSAR; molecular docking; iron chelation; dual COX-2 and 5-LOX inhibitors; ADMET prediction; BIOLOGICAL EVALUATION; SEMIEMPIRICAL METHODS; VALIDATION; 5-LIPOXYGENASE; ANALOGS; CYCLOOXYGENASE-2; OPTIMIZATION; PARAMETERS; PHENOTYPE; ALGORITHM;
D O I
10.2174/1570180818666210714161908
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Inflammation is a critical component of many disease progressions, such as malignancy, cardiovascular and rheumatic diseases. The inhibition of inflammatory mediators synthesis by modulation of cyclooxygenase (COX) and lipoxygenase (LOX) pathways provides challenging strategy for development of more effective drugs. Objective: The aim of this study was to design dual COX-2 and 5-LOX inhibitors with iron-chelating properties using a combination of ligand-based (three-dimensional quantitative structure-activity relationship (3D-QSAR)) and structure-based (molecular docking) methods. Methods: The 3D-QSAR analysis was applied on a literature dataset consisting of 28 dual COX-2 and 5-LOX inhibitors in Pentacle software. The quality of developed COX-2 and 5-LOX 3D-QSAR models were evaluated by internal and external validation methods. The molecular docking analysis was performed in GOLD software, while selected ADMET properties were predicted in ADMET predictor software. Results: According to the molecular docking studies, the class of sulfohydroxamic acid analogues, previously designed by 3D-QSAR, were clustered as potential dual COX-2 and 5-LOX inhibitors with iron-chelating properties. Based on the 3D-QSAR and molecular docking, 1j, 1g and 1l were selected as the most promising dual COX-2 and 5-LOX inhibitors. According to the in silico ADMET predictions, all compounds had ADMET_Risk score less than 7 and CYP_Risk score lower than 2.5. Designed compounds were not estimated as hERG inhibitors and 1j had improved intrinsic solubility (8.704) in comparison to the dataset compounds (0.411-7.946). Conclusion: By combining 3D-QSAR and molecular docking, three compounds (1j, 1g and 1l) were selected as the most promising designed dual COX-2 and 5-LOX inhibitors, for which good activity, as well as favourable ADMET properties and toxicity, are expected.
引用
收藏
页码:279 / 292
页数:14
相关论文
共 50 条
  • [41] Ligand-Guided Investigation of a Series of Formamidine-Based Thiuram Disulfides as Potential Dual-Inhibitors of COX-1and COX-2
    Oladipo, Segun D.
    Akinpelu, Olayinka, I
    Omondi, Bernard
    CHEMISTRY & BIODIVERSITY, 2023, 20 (01)
  • [42] Studies on the Dual Activity of EGFR and HER-2 Inhibitors Using Structure-Based Drug Design Techniques
    de Angelo, Rafaela Molina
    Almeida, Michell de Oliveira
    de Paula, Heberth
    Honorio, Kathia Maria
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (12)
  • [43] Predicting Potential Endocrine Disrupting Chemicals Binding to Estrogen Receptor α (ERα) Using a Pipeline Combining Structure-Based and Ligand-Based in Silico Methods
    Sellami, Asma
    Montes, Matthieu
    Lagarde, Nathalie
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (06) : 1 - 28
  • [44] Exploration of anti-inflammatory activity of pyrazolo[3,4-d]pyrimidine/ 1,2,4-oxadiazole hybrids as COX-2, 5-LOX and NO release inhibitors: Design, synthesis, in silico and in vivo studies
    Aziz, Marwa A.
    Salem, Ibrahim M.
    Al-Awadh, Mohammed A.
    Alharbi, Abdulrahman S.
    Abouzed, Deiaa E. Elsayed
    Allam, Rasha M.
    Ahmed, Osama A. A.
    Ibrahim, Tarek S.
    Abuo-Rahma, Gamal El-Din A.
    Mohamed, Mamdouh F. A.
    BIOORGANIC CHEMISTRY, 2025, 156
  • [45] Combined structure and ligand-based design of dual BACE-1/GSK-3β inhibitors for Alzheimer's disease
    Bajad, Nilesh Gajanan
    Swetha, Rayala
    Singh, Ravi
    Ganeshpurkar, Ankit
    Gutti, Gopichand
    Singh, Ravi Bhushan
    Kumar, Ashok
    Singh, Sushil Kumar
    CHEMICAL PAPERS, 2022, 76 (12) : 7507 - 7524
  • [46] Ligand-based and structure-based studies to develop predictive models for SARS-CoV-2 main protease inhibitors through the 3d-qsar.com portal
    Proia, Eleonora
    Ragno, Alessio
    Antonini, Lorenzo
    Sabatino, Manuela
    Mladenovic, Milan
    Capobianco, Roberto
    Ragno, Rino
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2022, 36 (07) : 483 - 505
  • [47] Discovery of novel p90 ribosomal S6 kinase 2 inhibitors for potential cancer treatment through ligand-based and structure-based virtual screening methods
    Zhao, Yue
    Chen, Rui-fang
    Deng, Zhen-Ke
    Zhang, Liu-Xia
    Cheng, Yan
    Chen, Alex F.
    Cao, Dong-Sheng
    CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS, 2021, 217
  • [48] Structural Probing, Screening and Structure-Based Drug Repositioning Insights into the Identification of Potential Cox-2 Inhibitors from Selective Coxibs
    Bommu, Uma Devi
    Konidala, Kranthi Kumar
    Pamanji, Rishika
    Yeguvapalli, Suneetha
    INTERDISCIPLINARY SCIENCES-COMPUTATIONAL LIFE SCIENCES, 2019, 11 (02) : 153 - 169
  • [49] Discovery of novel dual acetylcholinesterase and butyrylcholinesterase inhibitors using machine learning and structure-based drug design
    Tripathi, Manish Kumar
    Bhardwaj, Bhagwati
    Waiker, Digambar Kumar
    Tripathi, Avanish
    Shrivastava, Sushant Kumar
    JOURNAL OF MOLECULAR STRUCTURE, 2023, 1286
  • [50] Ligand-Based Virtual Screening Using Tailored Ensembles: A Prioritization Tool for Dual A2A Adenosine Receptor Antagonists/Monoamine Oxidase B Inhibitors
    Morales Helguera, Aliuska
    Perez-Castillo, Yunierkis
    Cordeiro, M. Natalia D. S.
    Tejera, Eduardo
    Paz-y-Mino, Cesar
    Sanchez-Rodriguez, Aminael
    Teijeira, Marta
    Ancede-Gallardo, Evys
    Cagide, Fernando
    Borges, Fernanda
    Cruz-Monteagudo, Maykel
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (21) : 3082 - 3096